<h4>Background</h4>Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia. This evidence concerns the gene BTK and Waldenstrom macroglobulinemia.